AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22906371
Drug: Bone-anchored maxillary
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-anchored maxillary expander (BAME) treatment
Trial: 21046863
Drug: Ten minute
RxNorm normalized name: Tagetes minuta flower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten minute medication review by a general practitioner
Trial: 17582921
Drug: Human papillomavirus
RxNorm normalized name: human papillomavirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human papillomavirus vaccine
Trial: 27663567
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (control)
Trial: 7782463
Drug: Exner administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exner administration
Trial: 7782463
Drug: first Exner
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: first Exner administration
Trial: 7782463
Drug: Rapaport administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapaport administration
Trial: 2184796
Drug: High-dose levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose levothyroxine sodium added to a stable regimen of medications
Trial: 31615585
Drug: Prucalopride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (1 mg)
Trial: 25410983
Drug: ALA-mediated PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-mediated PDT (20% ALA solution, 1.5 h incubation, 630 nm red light, 80 J/cm(2))
Trial: 19858394
Drug: VMP (bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMP (bortezomib 1.3 mg/m², melphalan 9 mg/m², prednisone 60 mg/m²)
Trial: 11712719
Drug: Single-session music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session music therapy interventions
Trial: 12787301
Drug: Montelukast 5
RxNorm normalized name: montelukast 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 5 mg
Trial: 9024176
Drug: Montelukast 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 20 mg
Trial: 9039239
Drug: Montelukast 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 100 mg
Trial: 9039239
Drug: Montelukast 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 250 mg
Trial: 15332389
Drug: Montelukast 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 40 mg
Trial: 9024176
Drug: Montelukast 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 200 mg
Trial: 3722374
Drug: Frigid air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frigid air inhalation during exercise
Trial: 10529124
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A 2.5 mg/kg/day
Trial: 10529124
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A 1.5 mg/kg/day
Trial: 29493047
Drug: Epirubicin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin treatment group
Trial: 15886860
Drug: Coca Cola
RxNorm normalized name: cola extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coca Cola (2.5 l per day)
Trial: 15886860
Drug: Semi-skimmed milk
RxNorm normalized name: Calcium fortified semi-skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-skimmed milk (2.5 l per day)
Trial: 11803087
Drug: Cell culture-derived
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell culture-derived vaccine
Trial: 9240689
Drug: Egg-derived vaccine
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-derived vaccine
Trial: 10404100
Drug: PSA >/=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA >/= 3 ng/ml as a direct biopsy indicator
Trial: 10404100
Drug: PSA <
RxNorm normalized name: Prostate-Specific Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA < 4 ng/ml with DRE and TRUS
Trial: 10404100
Drug: Logistic-regression model
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic-regression model predicting cancers for PSA < 4 ng/ml
Trial: 7587256
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 0.037 g/kg bolus followed by 0.025 g/kg/hr infusion
Trial: 7587256
Drug: Amiodarone 5
RxNorm normalized name: amiodarone 50 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 5 mg/kg bolus and 10 mg/kg/24-hr infusion
Trial: 6249047
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose (experiment A)
Trial: 30358116
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg + Dutasteride 0.5 mg + Imidafenacin 0.2 mg (TDI)
Trial: 29352704
Drug: High-dose E1224
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose E1224 (4000 mg over 8 weeks)
Trial: 29352704
Drug: Low-dose E1224
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose E1224 (2000 mg over 8 weeks)
Trial: 29352704
Drug: Short-dose E1224
RxNorm normalized name: short ragweed pollen extracts
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-dose E1224 (2400 mg over 4 weeks + 4 weeks placebo)
Trial: 29352704
Drug: Benznidazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole (5 mg/kg per day for 60 days)
Trial: 29352704
Drug: Placebo (E1224-matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (E1224-matched tablets for 8 weeks)
Trial: 22301195
Drug: Citalopram (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (target dose of 30 mg/d)
Trial: 9015133
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of 5 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Trial: 9015133
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of 10 mg Cr(VI)/L in drinking water (0.5 L swallowed in 2 min)
Trial: 9015133
Drug: Repeated exposure
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated exposure to 5 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Trial: 9015133
Drug: Repeated exposure
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated exposure to 10 mg Cr(VI)/L in drinking water (1 L/d for 3 days, 3 doses of 0.33 L each day at 6-h intervals)
Trial: 9015133
Drug: Overall ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall ingestion of Cr(VI) at 5 and 10 mg Cr(VI)/L
Trial: 24069533
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab treatment
Trial: 26027814
Drug: Daily conversational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily conversational interactions using remote video telecommunications software
Trial: 16740812
Drug: Timely patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely patient feedback in the form of a letter providing recent patient-specific symptoms, medication, and health service use combined with guideline-based recommendations for changes in therapy.
Trial: 15494100
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E(2)V + 2.5 mg MPA
Trial: 15494100
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E(2)V + 5 mg MPA
Trial: 11731187
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E(2) + 1 mg NETA
Trial: 11731187
Drug: E(2)V/MPA (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2)V/MPA (increased to 2 mg after 6 months)
Trial: 11731187
Drug: All dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose combinations
Trial: 8607227
Drug: Terazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1 mg daily for 3 days, then 2 mg daily for 25 days, titrated to 5 or 10 mg if needed)
Trial: 1544220
Drug: Interferon‐alpha 2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐alpha 2b (IFN‐alpha 2b) treatment, 3 x 10(6) U three times weekly for 36 weeks
Trial: 1544220
Drug: Interferon‐alpha 2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐alpha 2b (IFN‐alpha 2b) treatment
Trial: 3907893
Drug: Third-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-line therapy (general)
Trial: 30468238
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (16 g of resistant starch Hi‐Maize® 260)
Trial: 24795475
Drug: Single vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccine dose of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Trial: 24795475
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of unadjuvanted split‐virus H1N1 A/California/07/2009 influenza vaccine
Trial: 22613104
Drug: Compound prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound prescription (radix astragali + codonopsis pilosula + tortoise plastron)
Trial: 20830787
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (PEG‐IFN with lamivudine)
Trial: 18855259
Drug: Amiloride 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 2.5-5 mg/day
Trial: 18855259
Drug: Enalapril 10-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-20 mg/day
Trial: 15700156
Drug: Medical personnel's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical personnel's evaluation of therapy goals
Trial: 10355867
Drug: L-arginine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine intake (3.8 g/d) during diet B
Trial: 10355867
Drug: Nitrate/nitrite-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate/nitrite-free diet with no L-arginine intake during diet A
Trial: 31094588
Drug: Desogestrel 75
RxNorm normalized name: desogestrel 75 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel 75 µg
Trial: 29045941
Drug: Other antihypertensives
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensives
Trial: 23721750
Drug: 40 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/l carbohydrate, 20 g/l milk protein solution (CP20)
Trial: 23721750
Drug: 20 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/l carbohydrate, 40 g/l milk protein solution (CP40)
Trial: 23721750
Drug: 60 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/l carbohydrate solution (C)
Trial: 15569122
Drug: Control (alpha-interferon/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (alpha-interferon/ribavirin therapy)
Trial: 8396086
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg od for 3 days)
Trial: 8396086
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg tid for 10 days)
Trial: 21852334
Drug: Home monitoring
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home monitoring (HM) with daily spirometry and medical feedback
Trial: 9196992
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test (0.1 U/kg of crystalline insulin)
Trial: 9196992
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose tolerance test (0.3 g glucose/kg followed by 0.02 U/kg of crystalline insulin)
Trial: 1933160
Drug: Bard Biocath
RxNorm normalized name: IRRIGATION KIT BARD #750301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bard Biocath catheter (16 F 10‐ml balloon)
Trial: 1933160
Drug: Silastic catheter
RxNorm normalized name: CATHETER SILASTIC 14FR 5CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silastic catheter (16 F 10‐ml balloon)
Trial: 24934738
Drug: Two-session self-hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-session self-hypnosis training intervention with recordings and brief weekly reminder telephone calls
Trial: 23900128
Drug: 800ml oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800ml oral carbohydrate fluid 8 h before the operation and 400ml oral carbohydrate fluid 2 h before the operation
Trial: 23900128
Drug: Stopped oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopped oral implementation 8 h before the operation
Trial: 30167644
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 600 mg
Trial: 21062637
Drug: Ketamine (0.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.26 mg/kg bolus followed by 0.25 mg/kg IV infusion)
Trial: 17267590
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of Escherichia coli endotoxin (0.3 ng/kg)
Trial: 17267590
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of Escherichia coli endotoxin (0.3 ng/kg over 4 hours)
Trial: 769550
Drug: Tobramycin at
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin at a daily dose of 1.2 mg/kg body weight, administered by intramuscular injection at 8 or 12 hour intervals
Trial: 31493177
Drug: Erlotinib induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib induction at 150 mg/day for 3 months followed by cytotoxic chemotherapy (platinum plus pemetrexed, with or without bevacizumab)
Trial: 31493177
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after erlotinib induction
Trial: 25946126
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 and PTA 5289 lozenges (108 CFU of each strain/lozenge)
Trial: 21240026
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment program of obesity
Trial: 21240026
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment program of obesity
Trial: 31666688
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 20 ppm
Trial: 14530859
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil (0.35 mg/kg over 20 min)
Trial: 10965414
Drug: Digoxin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.5 mg) with DHEC (20 mg)
Trial: 10965414
Drug: Digoxin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.5 mg) without DHEC
Trial: 8774208
Drug: Isoniazid chemoprophylaxis
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid chemoprophylaxis (10 to 15 mg/kg, twice-weekly)
Trial: 29029210
Drug: lesinurad 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lesinurad 400 mg daily
Trial: 11181149
Drug: Interleukin (IL)-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin (IL)-2 immunotherapy (4.5x106 IU twice daily for 5 days every 6 weeks)
Trial: 9802132
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg/day)
Trial: 27016659
Drug: Active sequential
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active sequential bilateral rTMS
Trial: 23613825
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng 1 g day(-1)
Trial: 23613825
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng 2 g day(-1)
Trial: 23613825
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng 1 g
Trial: 15195497
Drug: Subcutaneous tryptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tryptorelin depot (Decapeptyl 3.75)
Trial: 15195497
Drug: Subcutaneous tryptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tryptorelin acetate daily (Decapeptyl 0.1 mg)
Trial: 15195497
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg tryptorelin acetate daily from day 21 of the cycle
Trial: 11468228
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 treatment
Trial: 8297196
Drug: Single-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose treatment with 1200 mg of norfloxacin
Trial: 8297196
Drug: Multiple-day treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-day treatment with 400 mg of norfloxacin twice daily for 7 days
Trial: 3177373
Drug: Continuous vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous vancomycin therapy (1-g loading dose followed by 30 mg/L dialysate effluent)
Trial: 3177373
Drug: Intermittent vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent vancomycin therapy (2 doses of 30 mg vancomycin/kg body weight, initial dose at diagnosis and second dose 1 week later)
Trial: 4392503
Drug: Alpha-receptor blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-receptor blocking drugs (phentolamine and phenoxybenzamine)
Trial: 4392503
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride (intravenous infusion)
Trial: 22702540
Drug: Erythropoiesis stimulating
RxNorm normalized name: Erythropoiesis stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis stimulating agents (ESAs)
Trial: 27770799
Drug: Oral bicarbonate
RxNorm normalized name: sodium bicarbonate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bicarbonate to achieve serum bicarbonate levels of 24-28 mmol/L
Trial: 23020102
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention on caregivers' feeding practices, including enhanced home-prepared recipes and food preparation and hygiene through group training, counselling, and home visits.
Trial: 16724579
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of zidovudine (AVIRO-Z 300 mg tablet)
Trial: 16724579
Drug: Innovator product
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator product (Retrovir tablet)
Trial: 11238508
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol daily
Trial: 11238508
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol plus 10 mg dydrogesterone daily
Trial: 9542398
Drug: Immunological rehabilitation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunological rehabilitation through various therapeutic methods including drugs, plasmapheresis, hemosorption, electrophoresis, ultrasound.
Trial: 8001095
Drug: Nonionic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic low osmolar contrast agent (iomeprol)
Trial: 8001095
Drug: Ionic contrast
RxNorm normalized name: IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic contrast agent (meglumine diatrizoate)
Trial: 3183633
Drug: Daily acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily acyclovir chemosuppression for 1 year
Trial: 3183633
Drug: Intermittent acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent acyclovir therapy (placebo group)
Trial: 15840666
Drug: THEO (theophylline)
RxNorm normalized name: theophylline Extended Release Oral Capsule [Theo-24]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THEO (theophylline) with loop diuretic (LD)